

## AHI granted extension to Nasdaq Shareholders' Equity Re-Compliance Period

Advanced Health Intelligence Ltd (ASX:AHI) (NASDAQ:AHI) ("AHI" or the "Company") would like to inform the market that the Company has been granted an extension to the Nasdaq shareholders' equity deficiency re-compliance period.

As previously notified to the ASX on 8 November 2023, the Company received a deficiency notification letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC ("Nasdaq"), indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(b) (the "Rule") requiring it to maintain a minimum of US\$2,500,000 in net shareholders' equity, \$35,000,000 market value of listed securities, or \$500,000 net income from continuing operations.

In the Company's Form 20-F filing for the year ended 30 June 2023, with the SEC in the US, the Company reported net shareholders' equity of A\$2,027,882 (approximately US\$1,344,485 using the exchange rate reported by the Reserve Bank of Australia as at 30 June 2023).

On 12 March 2024, AHI received notification from the Listing Qualifications Staff of Nasdaq indicating that the Company had been granted an extension of time to regain compliance with the Rule. The terms of the extension are that the Company must complete a financing transaction and evidence compliance with the Rule to Nasdaq on or before **6 May 2024**. In the event that the Company does not satisfy this requirement, the Listing Qualifications Staff of Nasdaq will provide written notification that the Company's securities will be delisted from Nasdaq.

Following re-compliance with the Rule, Nasdaq has advised that it will continue to monitor the Company's ongoing compliance with the stockholders' equity requirement and, if at the time of its next periodic report the Company does not evidence compliance, that the Company may be subject to delisting from Nasdaq.

If the Company fails to evidence compliance with the Rule upon filing its periodic report for the period ended 30 June 2024 with the SEC and Nasdaq, the Company may be subject to delisting from Nasdaq.

Nasdaq's written notice does not affect the listing or trading of the Company's ADSs on Nasdaq at this time, and the Company will continue evaluating its alternatives to resolve this listing deficiency.

The Chairman and Chief Executive Officer of Advanced Health Intelligence Ltd have approved this announcement.

For more information, please contact:

Scott Montgomery
Chief Executive Officer
Advanced Health Intelligence Ltd
E: admin@ahi.tech

Vlado Bosanac
Founder/Head of Strategy
Advanced Health Intelligence Ltd
E: admin@ahi.tech

## **About Advanced Health Intelligence Ltd**

Advanced Health Intelligence (AHI) delivers scalable health assessment, risk stratification and digital triage capabilities to healthcare providers, insurers, employers, and government agencies worldwide via our proprietary technology and processes.

Since 2014, AHI has been delivering Health-tech innovation via a smartphone, starting with the world's first on-device body dimensioning capability. AHI has developed a patented technology, showcasing the next frontier in digitising healthcare with a suite of componentised solutions, culminating in:

 Body dimension and composition assessment to identify the comorbidities of obesity, such as diabetes risk estimates.

## Market Announcement 13 March 2024



- Blood biomarker prediction, including HbA1C, HDL, LDL, and 10-year mortality risk.
- Transdermal Optical Imaging to return vital signs and cardiovascular disease risk estimates.
- On-device dermatological skin identification across 588 skin conditions across 133 categories (inc. Melanoma); and
- Assisting partners in delivering personalised therapeutic and non-therapeutic health coaching to improve daily habits and build health literacy.

Our world-class team of subject matter experts in machine learning, AI, computer vision, and medically trained data scientists ensure that AHI's technology is at the forefront of innovation and the needs of our consumers.

With a focus on impact at scale, AHI is proud to showcase this milestone in digital healthcare transformation, delivering a biometrically derived triage solution accessible on and via a smartphone. With these advanced technologies, AHI helps its partners identify risks across their consumers and triage them into right-care pathways for proactive health management at a population scale.

For more information, please visit: www.ahi.tech